CN114788809A - Loratadine liquid preparation - Google Patents
Loratadine liquid preparation Download PDFInfo
- Publication number
- CN114788809A CN114788809A CN202210085001.5A CN202210085001A CN114788809A CN 114788809 A CN114788809 A CN 114788809A CN 202210085001 A CN202210085001 A CN 202210085001A CN 114788809 A CN114788809 A CN 114788809A
- Authority
- CN
- China
- Prior art keywords
- weight
- loratadine
- parts
- liquid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The invention relates to a loratadine liquid preparation. Specifically, the invention provides a loratadine liquid preparation which comprises loratadine, a flavoring agent, a stabilizing agent and a solvent. The liquid loratadine hydrobromide preparation provided by the invention has excellent stability.
Description
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a loratadine liquid preparation.
Background
Loratadine is an antihistamine drug commonly used for treating allergic symptoms, such as allergic rhinitis, acute or chronic urticaria, allergic conjunctivitis, pollinosis and other allergic dermatoses, has a CAS number of 79794-75-5, and has the following structural formula:
the existing loratadine preparation mainly comprises a solid preparation such as loratadine tablets and a liquid preparation such as loratadine syrup, wherein the solid preparation such as the loratadine tablets relate to the dissolution of the medicine, and have slow effect, poor content uniformity and inconvenient administration. For liquid preparations such as loratadine syrup, the loratadine can quickly exert the treatment effect because the problem of drug dissolution is not involved, and the liquid preparations are convenient to take and have strong patient compliance, so the loratadine liquid preparations such as syrup can effectively exert the treatment effect of loratadine and improve the patient compliance.
However, the existing liquid formulations of loratadine also have many disadvantages, such as that the stability of loratadine syrup is easily affected by various factors, especially, light and heat, resulting in decreased contents and increased impurities, poor stability, in order to improve the stability, the existing loratadine liquid preparation is filled in a brown bottle and a large amount of preservative is added, and is protected from light and high temperature storage, not only increases the production, packaging, transportation and storage costs of liquid preparations such as syrups, and because the liquid loratadine preparation such as syrup is packed in the brown bottle, the characteristics of the liquid loratadine preparation such as syrup in the brown bottle, such as clarity, whether particles are precipitated or not, mildew, rancidity, discoloration, foreign matters, gas generation and other deterioration phenomena are difficult to be simply, quickly and effectively observed by a patient before the liquid loratadine preparation is purchased or used, and the problem of medication safety is easily caused.
Therefore, there is a need in the art to develop a liquid formulation of loratadine having excellent stability.
Disclosure of Invention
The invention aims to provide a loratadine liquid preparation with excellent stability.
In a first aspect of the invention, a loratadine liquid preparation is provided, which comprises loratadine, a flavoring agent, a stabilizing agent and a solvent.
Preferably, the liquid formulation is an oral formulation.
Preferably, the liquid formulation is an oral solution.
Preferably, the loratadine is present in an amount of 0.02-0.5 wt%, more preferably 0.05-0.2 wt%, more preferably 0.05-0.15 wt%, more preferably 0.08-0.12 wt%, most preferably 0.1 wt%, based on the weight of the liquid loratadine formulation.
Preferably, the loratadine is present in an amount of 0.2 to 5 parts by weight, more preferably 0.5 to 2 parts by weight, still more preferably 0.5 to 1.5 parts by weight, still more preferably 0.8 to 1.2 parts by weight, most preferably 1 part by weight.
Preferably, the flavoring agent is sucralose.
Preferably, the sucralose is contained in an amount of 0.02 to 0.5 wt%, more preferably 0.05 to 0.2 wt%, more preferably 0.05 to 0.15 wt%, more preferably 0.06 to 0.1 wt%, most preferably 0.08 wt%, based on the weight of the loratadine liquid preparation.
Preferably, the sucralose is present in an amount of 0.2 to 5 parts by weight, more preferably 0.5 to 2 parts by weight, more preferably 0.5 to 1.5 parts by weight, more preferably 0.6 to 1 part by weight, and most preferably 0.8 part by weight.
Preferably, the stabilizing agent is tartaric acid, sorbitol, sodium chloride and hydroxypropyl methylcellulose.
Preferably, the tartaric acid is present in an amount of 0.1-2 wt%, more preferably 0.1-1 wt%, more preferably 0.2-0.6 wt%, more preferably 0.3-0.5 wt%, most preferably 0.4 wt%, based on the weight of the liquid loratadine formulation.
Preferably, the tartaric acid is 1-20 parts by weight, more preferably 1-10 parts by weight, more preferably 2-6 parts by weight, more preferably 3-5 parts by weight, most preferably 4 parts by weight.
Preferably, the sorbitol is present in an amount of 1 to 5 wt%, more preferably 2 to 4 wt%, more preferably 2.5 to 3.5 wt%, more preferably 2.8 to 3.2 wt%, most preferably 3 wt%, based on the weight of the liquid loratadine formulation.
Preferably, the sorbitol is 10 to 50 parts by weight, more preferably 20 to 40 parts by weight, more preferably 25 to 35 parts by weight, more preferably 28 to 32 parts by weight, most preferably 30 parts by weight.
Preferably, the sodium chloride is present in an amount of 0.2 to 2.0 wt%, more preferably 0.5 to 1.5 wt%, more preferably 0.6 to 1.0 wt%, more preferably 0.7 to 0.9 wt%, most preferably 0.8 wt%, based on the weight of the liquid loratadine formulation.
Preferably, the sodium chloride is present in an amount of 2 to 20 parts by weight, more preferably 5 to 15 parts by weight, more preferably 6 to 10 parts by weight, more preferably 7 to 9 parts by weight, most preferably 8 parts by weight.
Preferably, the hydroxypropyl methylcellulose is present in an amount of 0.2 to 2 wt.%, more preferably 0.2 to 1.0 wt.%, more preferably 0.4 to 0.8 wt.%, more preferably 0.5 to 0.7 wt.%, most preferably 0.6 wt.%, based on the weight of the liquid loratadine formulation.
Preferably, the hydroxypropyl methylcellulose is 2-20 parts by weight, more preferably 2-10 parts by weight, more preferably 4-8 parts by weight, more preferably 5-7 parts by weight, and most preferably 6 parts by weight.
Preferably, the solvent comprises glycerol, ethanol and water.
Preferably, the glycerol is present in an amount of 2 to 6 wt%, more preferably 3 to 5 wt%, more preferably 3.5 to 4.5 wt%, more preferably 3.8 to 4.2 wt%, most preferably 4.0 wt%, based on the weight of the liquid loratadine formulation.
Preferably, the glycerol is 20 to 60 parts by weight, more preferably 30 to 50 parts by weight, more preferably 35 to 45 parts by weight, more preferably 38 to 42 parts by weight, most preferably 40 parts by weight.
Preferably, the ethanol is present in an amount of 0.5 to 4 wt%, more preferably 1 to 3 wt%, more preferably 1.5 to 2.5 wt%, more preferably 1.8 to 2.2 wt%, most preferably 2.0 wt%, based on the weight of the liquid loratadine formulation.
Preferably, the ethanol is 5 to 40 parts by weight, more preferably 10 to 30 parts by weight, more preferably 15 to 25 parts by weight, more preferably 18 to 22 parts by weight, most preferably 20 parts by weight.
Preferably, the water is purified water or water for injection.
Preferably, the water is 900-1100 parts by weight, preferably 920-1050 parts by weight, more preferably 900-1000 parts by weight, more preferably 920-970 parts by weight, and most preferably 930-960 parts by weight.
Preferably, the liquid loratadine preparation comprises loratadine, sucralose, glycerin, ethanol, tartaric acid, sorbitol, sodium chloride, hydroxypropyl methylcellulose and water.
Preferably, the liquid loratadine formulation comprises:
preferably, the liquid loratadine formulation comprises:
| components | Amount of the composition |
| Loratadine | 0.8 to 1.2 parts by weight of |
| Sucralose | 0.7 to 0.9 portion |
| Glycerol | 38 to 42 portions of |
| Ethanol | 18 to 22 portions of |
| Tartaric acid | 3.8 to 4.2 parts by weight of |
| Sorbitol | 28-32 parts by weight |
| Sodium chloride | 7 to 9 portions of |
| Hydroxypropyl methylcellulose | 5-7 parts by weight; and |
| water (I) | 920-960 parts by weight. |
Preferably, the liquid loratadine formulation comprises:
| components | Dosage of |
| Loratadine | 1.0 part by weight |
| Sucralose | 0.8 part by weight |
| Glycerol | 40 parts by weight of |
| Ethanol | 20 parts by weight of |
| Tartaric acid | 4 parts by weight of |
| Sorbitol | 30 parts by weight of |
| Sodium chloride | 8 parts by weight |
| Hydroxypropyl methylcellulose | 6 parts by weight; and |
| water (I) | 930-960 parts by weight. |
Preferably, the liquid loratadine formulation comprises:
| components | Amount of the composition |
| Loratadine | 1.0g |
| Sucralose | 0.8g |
| Glycerol | 40g |
| Ethanol | 20g |
| Tartaric acid | 4g |
| Sorbitol | 30g |
| Sodium chloride | 8g |
| Hydroxypropyl methylcellulose | 6g |
| Water (W) | To 1000 ml. |
Preferably, the unit of parts by weight is g.
Preferably, the loratadine liquid preparation is subpackaged in transparent containers.
Preferably, the transparent container comprises a transparent plastic container or a transparent glass container.
Preferably, the transparent plastic container comprises a transparent PET bottle.
In a second aspect of the present invention, there is provided a process for preparing a liquid loratadine formulation according to the first aspect of the present invention, said process comprising the steps of:
and mixing the loratadine, the flavoring agent, the stabilizing agent and the solvent to obtain the loratadine liquid preparation.
Preferably, the liquid loratadine preparation is prepared by the following method:
mixing loratadine, sucralose, glycerol, ethanol, tartaric acid, sorbitol, sodium chloride, hydroxypropyl methylcellulose and water to obtain the liquid loratadine preparation.
Preferably, after mixing, filtering through a microporous membrane to obtain the loratadine liquid preparation.
Preferably, the method comprises the steps of:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 40-50 ℃, adding 75-85% of water according to the formula amount, stirring and mixing at 40-50 ℃, adding sucralose, tartaric acid, sorbitol, sodium chloride and hydroxypropyl methylcellulose, stirring and mixing at 40-50 ℃, adding water to a constant volume to obtain a loratadine liquid preparation.
Preferably, water is added to the prepared volume, and the liquid loratadine preparation is obtained after filtration.
Preferably, the filtration is a microfiltration membrane filtration.
Preferably, the size of the filtration pores of the microporous filtration membrane is 0.10 to 1.0 μm, preferably 0.22 μm, 0.45 μm or 0.80 μm.
In a third aspect of the invention, there is provided a kit comprising a transparent container and a liquid formulation of loratadine according to the first aspect of the invention.
Preferably, said liquid formulation of loratadine according to the first aspect of the invention is dispensed into said transparent container.
Preferably, the transparent container contains the liquid formulation of loratadine according to the first aspect of the invention.
Preferably, the transparent container comprises a transparent plastic container or a transparent glass container.
Preferably, the transparent plastic container comprises a transparent PET bottle.
In a fourth aspect of the invention, there is provided the use of a liquid formulation of loratadine according to the first aspect of the invention for the manufacture of a medicament for the treatment of allergic symptoms.
Preferably, the allergic symptoms include symptoms associated with allergic rhinitis (e.g., sneezing, nasal discharge, nasal itching, nasal obstruction, and ocular itching and burning) and/or symptoms of allergic skin diseases (e.g., urticaria, pruritic skin diseases).
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments.
Detailed Description
The invention provides a loratadine liquid preparation which comprises loratadine, a flavoring agent, a stabilizing agent and a solvent. The loratadine liquid preparation provided by the invention has excellent thermal stability and light stability, so that the loratadine liquid preparation is convenient to store and transport. In addition, the loratadine liquid preparation does not contain sucrose and glucose which cause rapid rise of blood sugar, and is suitable for patients with hyperglycemia and diabetes to take, so that the people taking the loratadine liquid preparation is expanded.
Term(s) for
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, the terms "comprising," "including," "containing," and "containing" are used interchangeably and include not only closed-form definitions, but also semi-closed and open-form definitions. In other words, the term includes "consisting of … …", "consisting essentially of … …".
In the liquid loratadine formulations of the present invention, the weight content (wt%) or concentration (e.g., mg/mL) of each component is based on the weight or volume of the liquid loratadine formulation.
As used herein, the term "glycerol" refers to 1,2, 3-propanetriol.
As used herein, the terms "hydroxypropylmethylcellulose", "hydroxypropylmethylcellulose" and "hydroxypropylmethylcellulose" are used interchangeably and have the CAS number 9004-65-3.
As used herein, the term "PET" refers to polyester, and "pharmaceutical polyester bottles" and "pharmaceutical PET bottles" are used slowly.
As used herein, the term "part by weight" can be any fixed weight expressed in milligrams, grams, or kilograms (e.g., 1mg, 1g, or 1kg, etc.). For example, a composition consisting of 1 part by weight of component a and 9 parts by weight of component b may be a composition consisting of 1g of component a +9 g of component b, or 10 g of component a +90 g of component b. In the liquid loratadine formulation, the percentage content of a component (weight part of the component/the sum of all the weight parts) x 100% is such that the composition consisting of 1 part by weight of component a and 9 parts by weight of component b contains 10% of component a and 90% of component b.
Loratadine liquid preparation and preparation method thereof
The invention provides a loratadine liquid preparation which comprises loratadine, a flavoring agent, a stabilizing agent and a solvent.
The dosage form of the loratadine liquid preparation is preferably oral solution.
Specifically, the liquid loratadine formulations of the present invention are described above in the first aspect of the invention.
The loratadine liquid preparation can be subpackaged in transparent containers. The transparent container comprises a transparent plastic (such as PET) container or a transparent glass container.
Typically, the liquid loratadine formulation comprises:
| components | Amount of the composition |
| Loratadine | 0.5 to 1.5 parts by weight of |
| Sucralose | 0.4 to 1.2 parts by weight of |
| Glycerol | 30-50 parts by weight of |
| Ethanol | 15-25 parts by weight |
| Tartaric acid | 2-6 parts by weight |
| Sorbitol | 25-35 parts by weight |
| Sodium chloride | 6 to 10 parts by weight of |
| Hydroxypropyl methylcellulose | 4-8 parts by weight; and |
| water (W) | 920-960 parts by weight. |
Typically, the liquid loratadine formulation comprises:
| components | Amount of the composition |
| Loratadine | 0.8 to 1.2 parts by weight of |
| Sucralose | 0.7 to 0.9 part by weight |
| Glycerol | 38 to 42 parts by weight of |
| Ethanol | 18 to 22 portions of |
| Tartaric acid | 3.8 to 4.2 parts by weight of |
| Sorbitol | 28-32 parts by weight |
| Sodium chloride | 7 to 9 portions of |
| Hydroxypropyl methylcellulose | 5-7 parts by weight; and |
| water (W) | 920-960 parts by weight. |
Typically, the liquid loratadine formulation comprises:
| components | Amount of the composition |
| Loratadine | 1.0 part by weight |
| Sucralose | 0.8 part by weight |
| Glycerol | 40 parts by weight of |
| Ethanol | 20 parts by weight of |
| Tartaric acid | 4 parts by weight of |
| Sorbitol | 30 parts by weight of |
| Sodium chloride | 8 parts by weight |
| Hydroxypropyl methylcellulose | 6 parts by weight; and |
| water (I) | 930-960 parts by weight. |
Typically, the liquid loratadine formulation comprises:
| components | Amount of the composition |
| Loratadine | 1.0g |
| Sucralose | 0.8g |
| Glycerol | 40g |
| Ethanol | 20g |
| Tartaric acid | 4g |
| Sorbitol | 30g |
| Sodium chloride | 8g |
| Hydroxypropyl methylcellulose | 6g |
| Water (I) | To 1000 ml. |
The invention also provides a preparation method of the loratadine liquid preparation, which comprises the following steps:
and mixing the loratadine, the flavoring agent, the stabilizing agent and the solvent to obtain the loratadine liquid preparation.
In a preferred embodiment of the invention, the loratadine liquid preparation is prepared by the following method:
mixing loratadine, sucralose, glycerol, ethanol, tartaric acid, sorbitol, sodium chloride, hydroxypropyl methylcellulose and water to obtain the liquid loratadine preparation.
Preferably, after mixing, filtering through a microporous membrane to obtain the loratadine liquid preparation.
Preferably, the size of the filtration pores of the microporous filtration membrane is 0.10 to 1.0 μm, preferably 0.22 μm, 0.45 μm or 0.80 μm.
Typically, the liquid loratadine formulation is prepared by the following method:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 40-50 ℃, adding 75-85% of water according to the formula amount, stirring and mixing at 40-50 ℃, adding sucralose, tartaric acid, sorbitol, sodium chloride and hydroxypropyl methylcellulose, stirring and mixing at 40-50 ℃, adding water to a constant volume to obtain a loratadine liquid preparation.
The main excellent technical effects of the invention comprise:
1. the invention develops a loratadine liquid preparation which has light stability and can be simply subpackaged in a transparent container for storage and transportation without being subpackaged in a brown container for storage and transportation.
2. The loratadine liquid preparation developed by the invention has excellent thermal stability and is convenient to store and transport, so that the cost of storage, transportation and the like is reduced, and the economic benefit is improved.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, which are not specified under specific conditions, are generally performed under conventional conditions.
EXAMPLE 1 oral solution of loratadine
The formula of the loratadine oral solution of this example 1 is shown in table 1:
TABLE 1 composition of the prescription of loratadine oral solution (loratadine 1.0mg/ml)
| Components | Amount of the composition |
| Loratadine | 1.0g |
| Sucralose | 0.8g |
| Glycerol | 40g |
| Ethanol | 20g |
| Tartaric acid | 4g |
| Sorbitol | 30g |
| Sodium chloride | 8g |
| Hydroxypropyl methylcellulose | 6g |
| Purified water | To 1000ml |
The preparation method of the loratadine oral solution comprises the following steps:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 45 ℃, adding 80% of the formula amount of purified water, stirring and mixing at 45 ℃, adding sucralose, tartaric acid, sorbitol, sodium chloride and hydroxypropyl methyl cellulose, stirring and mixing at 45 ℃, adding the rest formula amount of purified water to a dosage volume, filtering through a 0.22 mu m microporous filter membrane to obtain a loratadine oral solution, and subpackaging in transparent PET bottles.
Comparative example 1 oral solution of loratadine
The prescription of the loratadine oral solution of this comparative example 1 is shown in table 2:
TABLE 2 composition of loratadine oral solution (loratadine 1.0mg/ml)
| Components | Amount of the composition |
| Loratadine | 1.0g |
| Sucralose | 0.8g |
| Glycerol | 40g |
| Ethanol | 20g |
| Tartaric acid | 4g |
| Sorbitol | 10g |
| Sodium chloride | 8g |
| Hydroxypropyl methylcellulose | 6g |
| Purified water | To 1000ml |
The preparation method of the loratadine oral solution comprises the following steps:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 45 ℃, adding 80% of the formula amount of purified water, stirring and mixing at 45 ℃, adding sucralose, tartaric acid, sorbitol, sodium chloride and hydroxypropyl methyl cellulose, stirring and mixing at 45 ℃, adding the rest formula amount of purified water to a dosage volume, filtering through a 0.22 mu m microporous filter membrane to obtain a loratadine oral solution, and subpackaging in transparent PET bottles.
Comparative example 2 oral loratadine solution
The formula of the loratadine oral solution of comparative example 2 is shown in table 3:
TABLE 3 composition of loratadine oral solution (loratadine 1.0mg/ml in specification)
The preparation method of the loratadine oral solution comprises the following steps:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 45 ℃, adding 80% of purified water according to the prescription amount, stirring and mixing at 45 ℃, adding sucralose, tartaric acid, sorbitol, sodium chloride and hydroxypropyl methylcellulose, stirring and mixing at 45 ℃, adding the rest purified water according to the prescription amount to a dosage volume, filtering through a 0.22 mu m microporous filter membrane to obtain a loratadine oral solution, and subpackaging in transparent PET bottles.
Comparative example 3 oral solution of loratadine
The prescription of the loratadine oral solution of this comparative example 3 is shown in table 4:
TABLE 4 composition of loratadine oral solution (loratadine 1.0mg/ml)
| Components | Amount of the composition |
| Loratadine | 1.0g |
| Sucralose | 0.8g |
| Glycerol | 40g |
| Ethanol | 20g |
| Tartaric acid | 4g |
| Sodium chloride | 8g |
| Purified water | To 1000ml |
The preparation method of the loratadine oral solution comprises the following steps:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 45 ℃, adding 80% of purified water according to the prescription amount, stirring and mixing at 45 ℃, adding sucralose, tartaric acid and sodium chloride, stirring and mixing at 45 ℃, adding the rest purified water according to the prescription amount to a dosage volume, filtering by a 0.22 mu m microporous filter membrane to obtain a loratadine oral solution, and subpackaging in transparent PET bottles.
Comparative example 4 oral solution of loratadine
The prescription of the loratadine oral solution of this comparative example 4 is shown in table 5:
TABLE 5 composition of the prescription of loratadine oral solution (loratadine 1.0mg/ml)
The preparation method of the loratadine oral solution comprises the following steps:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 45 ℃, adding 80% of the formula amount of purified water, stirring and mixing at 45 ℃, adding sucralose, tartaric acid, sodium chloride and hydroxypropyl methyl cellulose, stirring and mixing at 45 ℃, adding the rest of the formula amount of purified water to a fixed volume to a dosage volume, filtering through a 0.22 mu m microporous filter membrane to obtain a loratadine oral solution, and subpackaging in transparent PET bottles.
Comparative example 5 oral solution of loratadine
The prescription of the loratadine oral solution of this comparative example 5 is shown in table 6:
TABLE 6 prescription composition of loratadine oral solution (loratadine 1.0mg/ml)
| Components | Amount of the composition |
| Loratadine | 1.0g |
| Sucralose | 0.8g |
| Glycerol | 40g |
| Ethanol | 20g |
| Tartaric acid | 4g |
| Sorbitol | 30g |
| Sodium chloride | 8g |
| Purified water | To 1000ml |
The preparation method of the loratadine oral solution comprises the following steps:
mixing glycerol and ethanol, adding loratadine, stirring and mixing at 45 ℃, adding 80% of purified water according to the prescription amount, stirring and mixing at 45 ℃, adding sucralose, tartaric acid, sorbitol and sodium chloride, stirring and mixing at 45 ℃, adding the rest purified water according to the prescription amount to a dosage volume, filtering through a 0.22 mu m microporous filter membrane to obtain the loratadine oral solution, and subpackaging in transparent PET bottles.
Stability survey
1. Stability study of illumination factors
The loratadine content (%) and impurity content (%) were determined by HPLC (high performance liquid chromatography) with reference to the chinese pharmacopoeia formulation stability test guidelines, with light single factor examination under light (4500lx, 25 ℃) conditions for the stability of the loratadine oral solutions prepared in example 1 and comparative examples 1-5, which were packaged in clear PET bottles, after preparation (0 day), 10 days, and 30 days, wherein the loratadine content (%) was controlled to 90-100%, the single impurity content was controlled to 0.5% or less, and the total impurity content was controlled to 1.0% or less.
The results of examining the loratadine oral solutions prepared in example 1 and comparative examples 1-5 in clear PET bottles under light (4500lx, 25 ℃) are shown in table 7:
table 7 light factor stability examination of loratadine oral solutions prepared in example 1 and comparative examples 1-5
As can be seen from table 7, the loratadine oral solution prepared in example 1 has excellent light stability, and can be stored and transported simply by being dispensed in a transparent container, without being dispensed in a brown container to be stored and transported away from light.
2. Accelerated stability review
Referring to the guidelines of the stability test of the Chinese pharmacopoeia preparation, the stability of the loratadine oral solution (packaged in transparent PET bottles) prepared in example 1 after preparation (0 day), accelerated by 1, 3 and 6 months was examined by performing the accelerated stability test under the conditions of a temperature of 40 + -2 ℃ and a relative humidity of RH75 + -5%, and the content (%) of loratadine and the content (%) of impurities were measured by HPLC (high performance liquid chromatography), wherein the content (%) of loratadine was controlled to be 90-100%, the content of single impurities was controlled to be less than or equal to 0.5%, and the content of total impurities was controlled to be less than or equal to 1.0%.
Accelerated stability studies of the loratadine oral solutions prepared in example 1 are shown in table 8:
TABLE 8 accelerated stability (40. + -. 2 ℃ C., RH 75. + -. 5%) of loratadine oral solutions prepared in example 1
As can be seen from table 8, the loratadine oral solution prepared in example 1 has excellent accelerated stability, facilitating storage and transportation.
While the invention has been described in terms of a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made without departing from the spirit and scope of the invention.
Claims (10)
1. The liquid loratadine preparation is characterized by comprising loratadine, a flavoring agent, a stabilizing agent and a solvent.
2. The liquid loratadine formulation of claim 1 wherein the liquid loratadine formulation is an oral solution.
3. The liquid loratadine formulation of claim 1 wherein said flavoring agent is sucralose;
the stabilizer is tartaric acid, sorbitol, sodium chloride and hydroxypropyl methylcellulose; and/or
The solvent comprises glycerol, ethanol and water.
4. The liquid loratadine formulation according to claim 3 wherein the loratadine is present in an amount of 0.02-0.5 wt.%, more preferably 0.05-0.2 wt.%, more preferably 0.05-0.15 wt.%, more preferably 0.08-0.12 wt.%, most preferably 0.1 wt.%, based on the weight of the liquid loratadine formulation;
the content of the sucralose is 0.02-0.5 wt%, preferably 0.05-0.2 wt%, more preferably 0.05-0.15 wt%, more preferably 0.06-0.1 wt%, most preferably 0.08 wt%, based on the weight of the loratadine liquid preparation;
the content of the tartaric acid is 0.1-2 wt%, preferably 0.1-1 wt%, preferably 0.2-0.6 wt%, preferably 0.3-0.5 wt%, preferably 0.4 wt%, based on the weight of the loratadine liquid preparation;
the content of sorbitol is 1-5 wt%, preferably 2-4 wt%, more preferably 2.5-3.5 wt%, more preferably 2.8-3.2 wt%, most preferably 3 wt%, based on the weight of the loratadine liquid preparation;
the content of the sodium chloride is 0.2-2.0 wt%, preferably 0.5-1.5 wt%, preferably 0.6-1.0 wt%, preferably 0.7-0.9 wt%, preferably 0.8 wt%, based on the weight of the loratadine liquid preparation;
the content of the hydroxypropyl methylcellulose is 0.2-2 wt%, more preferably 0.2-1.0 wt%, more preferably 0.4-0.8 wt%, more preferably 0.5-0.7 wt%, most preferably 0.6 wt%, based on the weight of the loratadine liquid preparation;
the content of the glycerol is 2-6 wt%, preferably 3-5 wt%, preferably 3.5-4.5 wt%, preferably 3.8-4.2 wt%, preferably 4.0 wt%, based on the weight of the loratadine liquid preparation; and/or
The content of the ethanol is 0.5-4 wt%, preferably 1-3 wt%, more preferably 1.5-2.5 wt%, more preferably 1.8-2.2 wt%, most preferably 2.0 wt%, based on the weight of the loratadine liquid preparation.
5. The liquid loratadine formulation of claim 3 wherein the amount of loratadine is 0.2-5 parts by weight, more preferably 0.5-2 parts by weight, more preferably 0.5-1.5 parts by weight, more preferably 0.8-1.2 parts by weight, most preferably 1 part by weight;
the sucralose is 0.2 to 5 parts by weight, preferably 0.5 to 2 parts by weight, more preferably 0.5 to 1.5 parts by weight, more preferably 0.6 to 1 part by weight, most preferably 0.8 part by weight;
1-20 parts by weight of tartaric acid, preferably 1-10 parts by weight, more preferably 2-6 parts by weight, more preferably 3-5 parts by weight, and most preferably 4 parts by weight;
the sorbitol is 10 to 50 weight portions, preferably 20 to 40 weight portions, more preferably 25 to 35 weight portions, more preferably 28 to 32 weight portions, and most preferably 30 weight portions;
the sodium chloride is 2 to 20 parts by weight, preferably 5 to 15 parts by weight, more preferably 6 to 10 parts by weight, more preferably 7 to 9 parts by weight, most preferably 8 parts by weight;
the hydroxypropyl methyl cellulose is 2-20 parts by weight, preferably 2-10 parts by weight, more preferably 4-8 parts by weight, more preferably 5-7 parts by weight, most preferably 6 parts by weight;
the glycerol is 20-60 parts by weight, preferably 30-50 parts by weight, more preferably 35-45 parts by weight, more preferably 38-42 parts by weight, most preferably 40 parts by weight;
the ethanol accounts for 5 to 40 weight portions, preferably 10 to 30 weight portions, more preferably 15 to 25 weight portions, more preferably 18 to 22 weight portions, and most preferably 20 weight portions; and/or
The water content is 900-.
6. The liquid loratadine formulation of claim 1 wherein said liquid loratadine formulation comprises:
7. The liquid loratadine formulation of claim 1 wherein said liquid loratadine formulation comprises:
8. the liquid loratadine formulation of claim 1 wherein said liquid loratadine formulation comprises:
9. A kit comprising a transparent container and the liquid loratadine formulation of claim 1;
the liquid loratadine preparation is separately packaged in the transparent container.
10. Use of a liquid formulation of loratadine according to claim 1 for the preparation of a medicament for the treatment of allergic symptoms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210085001.5A CN114788809B (en) | 2022-01-25 | 2022-01-25 | Loratadine liquid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210085001.5A CN114788809B (en) | 2022-01-25 | 2022-01-25 | Loratadine liquid preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114788809A true CN114788809A (en) | 2022-07-26 |
| CN114788809B CN114788809B (en) | 2023-04-14 |
Family
ID=82459205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210085001.5A Active CN114788809B (en) | 2022-01-25 | 2022-01-25 | Loratadine liquid preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114788809B (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883479A (en) * | 2005-06-22 | 2006-12-27 | 北京德众万全医药科技有限公司 | A quantitative drop |
| US20080262017A1 (en) * | 2006-06-29 | 2008-10-23 | Ulloa Sergio R | Sugar-Free Storage-Stable Antihistaminic Syrups |
| CN101390860A (en) * | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | Desloratadine syrup and preparation method thereof |
| WO2014039903A2 (en) * | 2012-09-07 | 2014-03-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| CN104010657A (en) * | 2011-10-18 | 2014-08-27 | 科荣生生物科学公司 | Etanercept formulation stabilized with sodium chloride |
| CN104306329A (en) * | 2014-11-07 | 2015-01-28 | 石家庄科仁医药科技有限公司 | Bromhexine hydrochloride injection and preparation method and application thereof |
| WO2015189726A1 (en) * | 2014-06-10 | 2015-12-17 | Capsugel Belgium Nv | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use |
| WO2018122867A1 (en) * | 2016-12-27 | 2018-07-05 | Zim Laboratories Limited | Thin film formulations of 4-diphenylmethyl-1-piperazine derivatives and their salts |
| JP2018123114A (en) * | 2017-07-03 | 2018-08-09 | 協和発酵キリン株式会社 | Liquid pharmaceutical compositions comprising darbepoietin |
| CN109620799A (en) * | 2019-01-24 | 2019-04-16 | 成都欣捷高新技术开发股份有限公司 | Stable bromhexine hydrochloride liquid preparation composition and preparation method thereof |
| CN109641059A (en) * | 2016-08-23 | 2019-04-16 | 大塚制药株式会社 | Ophthalmic pharmaceutical compositions with improved antiseptic effect or photostability |
| CN110638750A (en) * | 2019-10-28 | 2020-01-03 | 深圳市贝美药业有限公司 | Preparation method of desloratadine medicine and preparation thereof |
| CN112220748A (en) * | 2020-10-26 | 2021-01-15 | 江苏阿尔法药业有限公司 | Desloratadine oral liquid preparation and preparation method thereof |
| CN113730336A (en) * | 2021-09-27 | 2021-12-03 | 浙江核力欣健药业有限公司 | Loratadine syrup and preparation method thereof |
-
2022
- 2022-01-25 CN CN202210085001.5A patent/CN114788809B/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883479A (en) * | 2005-06-22 | 2006-12-27 | 北京德众万全医药科技有限公司 | A quantitative drop |
| US20080262017A1 (en) * | 2006-06-29 | 2008-10-23 | Ulloa Sergio R | Sugar-Free Storage-Stable Antihistaminic Syrups |
| CN101390860A (en) * | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | Desloratadine syrup and preparation method thereof |
| CN104010657A (en) * | 2011-10-18 | 2014-08-27 | 科荣生生物科学公司 | Etanercept formulation stabilized with sodium chloride |
| WO2014039903A2 (en) * | 2012-09-07 | 2014-03-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| WO2015189726A1 (en) * | 2014-06-10 | 2015-12-17 | Capsugel Belgium Nv | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use |
| CN104306329A (en) * | 2014-11-07 | 2015-01-28 | 石家庄科仁医药科技有限公司 | Bromhexine hydrochloride injection and preparation method and application thereof |
| CN109641059A (en) * | 2016-08-23 | 2019-04-16 | 大塚制药株式会社 | Ophthalmic pharmaceutical compositions with improved antiseptic effect or photostability |
| WO2018122867A1 (en) * | 2016-12-27 | 2018-07-05 | Zim Laboratories Limited | Thin film formulations of 4-diphenylmethyl-1-piperazine derivatives and their salts |
| JP2018123114A (en) * | 2017-07-03 | 2018-08-09 | 協和発酵キリン株式会社 | Liquid pharmaceutical compositions comprising darbepoietin |
| CN109620799A (en) * | 2019-01-24 | 2019-04-16 | 成都欣捷高新技术开发股份有限公司 | Stable bromhexine hydrochloride liquid preparation composition and preparation method thereof |
| CN110638750A (en) * | 2019-10-28 | 2020-01-03 | 深圳市贝美药业有限公司 | Preparation method of desloratadine medicine and preparation thereof |
| CN112220748A (en) * | 2020-10-26 | 2021-01-15 | 江苏阿尔法药业有限公司 | Desloratadine oral liquid preparation and preparation method thereof |
| CN113730336A (en) * | 2021-09-27 | 2021-12-03 | 浙江核力欣健药业有限公司 | Loratadine syrup and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114788809B (en) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100311165B1 (en) | Pharmaceutical composition for treating depression containing pramifelsol | |
| US9532947B2 (en) | Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules | |
| CN111481501B (en) | Ketorolac tromethamine injection capable of reducing irritation and free of organic solvent | |
| WO2019130052A1 (en) | Liquid oral formulations for pde v inhibitors | |
| US20210228507A1 (en) | Phenylephrine Hydrochloride Compositions and Containers | |
| CN107952064B (en) | Pharmaceutical preparation containing polyethylene glycol lozenges and preparation method thereof | |
| US20210361593A1 (en) | Phytonadione compositions and related methods | |
| US8202898B1 (en) | Pharmaceutical composition | |
| CN114788809B (en) | Loratadine liquid preparation | |
| US20220378803A1 (en) | Injectable compositions of ursodeoxycholic acid | |
| JP4959335B2 (en) | Methylphenidate solution and related administration and manufacturing methods | |
| CN110664747A (en) | Injection of abidol hydrochloride and preparation method thereof | |
| EP2926816A1 (en) | Pharmaceutical composition comprising desloratadine and prednisolone and use thereof | |
| WO2023139464A1 (en) | A liquid pharmaceutical formulation of clonidine hydrochloride | |
| CN103690479B (en) | A kind of Glycopyrronium bromide injection and preparation method thereof | |
| CN114159387B (en) | Dextromethorphan hydrobromide oral solution | |
| JP2024500166A (en) | Stable liquid pharmaceutical composition containing a kudinoside compound | |
| EP3582765B1 (en) | Midodrine hydrochloride oral solution and uses thereof | |
| CN115569113B (en) | Valganciclovir hydrochloride oral solution | |
| CN114533664B (en) | Compound oral liquid preparation of dextromethorphan hydrobromide and guaiacol glyceryl ether | |
| RU2359669C1 (en) | Pharmaceutical composition in form of solution for injections, possessing cerebrovasodilating and nootropic activity, and method of its reception | |
| CN102274194B (en) | Pharmaceutical composition containing tropisetron compound and preparation method thereof | |
| EP3071202B1 (en) | A combination of dosage units for use in the treatment of pre-term labour condition | |
| CN115025041B (en) | Levocetirizine hydrochloride oral solution | |
| CN115518035B (en) | Ketorolac liquid composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |